ArticleJournal of thoracic disease2025
Preoperative C-reactive protein-augmented CONUT score as a better prognostic indicator than CONUT alone in non-small cell lung cancer across age groups.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preoperative nutritional status correlates with outcomes in malignancies. We previously identified the Controlling Nutritional Status (CONUT) score as a sensitive prognostic indicator in elderly non-small cell lung cancer (NSCLC) patients and proposed the C-reactive protein (CRP)-augmented combined CRP and CONUT (C-CONUT) score. The aim of this study was to evaluate whether the C-CONUT score is a more effective prognostic tool than the CONUT score in younger NSCLC patients across different age groups. Methods: In a retrospective single-center cohort from January 2012 to December 2022 (n=738), we evaluated CONUT and C-CONUT scores in NSCLC patients across three age cohorts (≤79, ≤75, and ≤65 years). Patients receiving neoadjuvant therapy, with stage 0/IIIB disease, or missing data were excluded. Receiver operating characteristic (ROC) curves determined optimal cutoff values; Kaplan-Meier and multivariable Cox regression assessed prognostic significance. Results: Median follow-up was 56 months. Optimal cutoffs: CONUT ≥2; C-CONUT ≥3. C-CONUT achieved the highest area under the curve (AUC) [0.654; 95% confidence interval (CI): 0.653-0.781; P<0.001], outperforming CONUT alone. While elevated CONUT was prognostic only in patients ≤79 years, C-CONUT remained significantly associated with overall survival (OS) in all age strata, including ≤75 and ≤65 years. In multivariate models, C-CONUT was an independent predictor in younger cohorts even when CONUT was not. Conclusions: The C-CONUT score may be a more promising prognostic indicator than CONUT alone in NSCLC patients aged ≤75 years; however, this exploratory study requires prospective validation to confirm these findings. As it derives from routine laboratory parameters, C-CONUT is a practical, non-invasive tool for preoperative risk stratification. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.